Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01188252 · ClinicalTrials.gov registry record · Phase 1
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
NCT01188252 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 112 participants.
The verdict
NCT01188252, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
Clinical study to determine safety, tolerability, to measure how the drug is metabolized by the body and to determine the maximum tolerated dose of BAY1000394 given in an intermittent 3 days on / 4 days off schedule to patients with advanced malignancies
Interventions
- DRUG Roniciclib (BAY1000394)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2010-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01188252
The ClinicalTrials.gov registry entry for NCT01188252 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Roniciclib (BAY1000394) is the first listed.
NCT01188252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01188252 about?
NCT01188252 is a clinical study titled "Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies". Clinical study to determine safety, tolerability, to measure how the drug is metabolized by the body and to determine the maximum tolerated dose of BAY1000394 given in an intermittent 3 days on / 4 days off schedule to patients with advanced malignancies
What is the current status of trial NCT01188252?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2010-08. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01188252?
The interventions under investigation include: Roniciclib (BAY1000394) (DRUG).
Who is sponsoring clinical trial NCT01188252?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.